Immuneering Phase 3 Pancreatic Cancer Trial Recruiting; Cash $198.6M
Immuneering Corporation reported Q1 2026 financial results and provided significant business updates, primarily focusing on its clinical pipeline. The company announced that its pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line metastatic pancreatic cancer is now recruiting patients, with the first patient dosing expected by mid-2026. Additionally, new survival data from the Phase 2a trial will be presented at the 2026 ASCO Annual Meeting, and a third-line pancreatic cancer patient demonstrated 27 months of progression-free survival with atebimetinib monotherapy. Immuneering ended Q1 2026 with a strong cash position of $198.6 million, providing an anticipated runway into 2029, while reporting a net loss of $13.5 million.
Key Highlights
- Pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in first-line metastatic pancreatic cancer is now recruiting patients.
- New survival data from Phase 2a trial (55 patients) to be presented at 2026 ASCO Annual Meeting on June 1.
- A third-line pancreatic cancer patient achieved 27 months progression-free survival with atebimetinib monotherapy.
- Immuneering ended Q1 2026 with $198.6 million in cash, cash equivalents, and marketable securities.
- The company anticipates its cash runway to be sufficient to fund operations into 2029.
- Net loss attributable to common stockholders for Q1 2026 was $13.5 million, or $0.21 per share.
- Research and Development expenses for Q1 2026 decreased to $10.6 million from $11.5 million YoY.
Price Impact
More from IMRX